The Evolving Treatment Paradigm for Stage I-IIIA NSCLC

A panel of lung cancer experts provides an overview of molecular testing in early-stage non-small cell lung cancer (NSCLC) and recommendations for biomarkers to test for and at what treatment stages to perform testing.

Jonathan Spicer, MD, explains the role of molecular testing in patients with stage I-IIIA NSCLC, and how it informs treatment decision-making.

Ignacio Wistuba, MD, leads the discussion on the role of liquid biopsies for molecular testing in early NSCLC.

The panel reviews updates in the treatment of stage I-IIIA NSCLC and discusses its impact in clinical practice.

Drs Wakelee, Sabari, and Wistuba review updated data on neoadjuvant treatment in NSCLC from key studies including CheckMate-816 and NADIM-2.

Joshua Sabari, MD, describes which stage groups of patients with NSCLC should receive neoadjuvant therapies, and which therapies are typically used.

Drs Bill W. Loo and Joshua Sabari discusses whether there is a role for any adjuvant therapies in NSCLC treatment, and which patients might benefit.

Key opinion leaders share their thoughts on data updates from the ADUARA trial on the use of osimertinib as an adjuvant therapy for NSCLC.

Drs Spicer and Sabari explain if and when they test patients with NSCLC for EGFR mutations after surgical resection.

Recommendations for community hospitals and physicians on the critically necessary molecular tests needed for patients with NSCLC.

The panel shares the data that excited them the most from ESMO 2022, and what to look forward to in the future.